Win­ners and losers at #ES­MO18

MU­NICH — As­traZeneca has fol­lowed up on its break­through ap­proval for Lyn­parza — the first of the PARP wave that ar­rived on the mar­ket 4 years ago — with the roll­out of im­pres­sive front­line da­ta for ovar­i­an can­cer.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER